Thread Content
By 2025, Sinopharm will adopt a dual-driven strategy of \"chemicals +\" and \"biotechnology +\", focusing on high-quality productive forces to deepen its efforts in cutting-edge fields. Key projects such as Tianjin Nylon New Materials and the joint-venture liquid methionine are progressing steadily, strengthening the advantages of the industrial chain ； The production capacity of perfluorohexyloctane is 45 tons per year; innovations in biotechnological fermentation help to develop green products, while digital transformation and AI pilot projects are carried out simultaneously to improve production efficiency. That year, the company completed the development of 92 new products, obtained 95 patents as well as numerous industry technology awards, and accelerated the transformation of its technological achievements ； By establishing deep collaborations with universities and enterprises both domestically and internationally, an open and innovative ecosystem is created. In terms of honors, it not only ranked first among the top 100 companies in the fine chemicals sector and received authoritative recognitions such as the Golden Bull Award, but its EcoVadis score also placed it in the top 5% globally. At the same time, the company actively fulfills its social responsibilities, having contributed 800 hours of volunteer service and donating over 5 million yuan in funds and goods. It also improves employee welfare benefits, delivering an outstanding annual performance through innovation, cooperation, and a sense of responsibility.